Vera Therapeutics announced that TRUTAKNA met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 trial for primary IgA nephropathy. In a 428-patient set, TRUTAKNA stabilized eGFR with a mean change of -0.1 mL/min/1.73m² versus -5.7 for placebo (p<0.0001) and reduced composite kidney disease progression by 76% (HR 0.24). The company plans to submit a supplemental BLA for full approval in Q4 2026, targeting potential approval in 2027. Vera Therapeutics is a commercial-stage biotechnology company developing treatments for autoimmune diseases.
